Donanemab, a new drug for Alzheimer disease has shown positive results in the clinical trial according to the study published in the New England Journal of Medicine.
Donanemab drug has been tested on 257 participants with early-stage Alzheimer, who were randomly assigned to receive either donanemab or placebo by intravenous infusion every four weeks for 76 weeks.
The researchers measured a change in a cognitive and functional score called the Integrated Alzheimer’s Disease Rating Scale (IADRS) which ranges from 0-144. The researchers also measured the change in amyloid-beta levels in the brain using emission tomography (PET) scans.
Donanemab is an antibody therapy from the US pharmaceutical giant Eli Lily which targets the abnormal clumps of protein called amyloid-beta that can build up in brain. Donanemab is given as an intravenous infusion once every four weeks. Patients need to have regular brain scans to monitor drug’s side effects, including brain swelling and bleeding.
There are significant side-effects of the donanemab. In the trial of drug, nearly a quarter of patients treated experienced with brain swelling or bleeding, compared with only 2% in the control group, though serious problems were rare. Four people died while taking part in the trial, three in the donanemab group and one in the control group.
In an age where technology and finance intersect at lightning speed, Luana Lopes Lara, a…
In a significant development for higher education in India, Victoria University (VU) from Australia is…
Many lakes around the world are known by special names because of their stories, beauty,…
Under Section 45ZL of the Reserve Bank of India Act, 1934, every quarter, India’s Monetary…
India hosts nearly 8% of the world’s biodiversity, making conservation crucial for ecological balance and…
Swaraj Kaushal, the former Governor of Mizoram, a noted senior advocate, and the husband of…